Federal Register / Vol. 80, No. 69 / Friday, April 10, 2015 / Notices 19329 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel. 

Date: May 7, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Peter Zelazowski, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH 6100 Executive 

Boulevard, Room 5B01, Bethesda, MD 

20892–9304, (301) 435–6902, 

peter.zelazowski@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: April 7, 2015. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–08294 Filed 4–9–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Date: Center for 

Inherited Disease Research Access 

Committee. 

Date: April 23, 2015. 

Time: 11:30 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Camilla E. Day, Ph.D., 

Scientific Review Officer, CIDR, National 

Human Genome Research Institute, National 

Institutes of Health, 5635 Fishers Lane, Suite 

4075, Bethesda, MD 20892, 301–402–8837, 

camilla.day@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: April 6, 2015. 

David Clary, 

Program Analyst, 

Office of Federal Advisory Committee 

Policy. 

[FR Doc. 2015–08213 Filed 4–9–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

Novel Immunotherapy for Cancer 

Treatment: Chimeric Antigen Receptors 

Targeting CD70 Antigen 

Description of Technology: Scientists 

at the National Institutes of Health have 

developed anti-CD70 chimeric antigen 

receptors (CARs) to treat cancers. CD70 

is an antigen that is expressed on a 

variety of human cancers such as renal 

cell carcinoma, glioblastoma, nonHodgkin’s lymphoma, and chronic 

lymphocytic leukemia. The anti-CD70 

CARs are hybrid proteins consisting of 

a receptor portion that recognizes CD70 

antigen, and intracellular T cell 

signaling domains selected to optimally 

activate the CAR expressing T cells. 

Genetically engineered T cells that 

express this CARs will bind to CD70 on 

the cancer cells and will be activated to 

induce an immune response that 

promotes robust tumor cell elimination 

when infused into cancer patients. This 

technology can rapidly generate a 

vigorous T-cell response from the 

patient’s own blood, targeting CD70 

expressing cancer cells, and potentially 

induce tumor rejection. 

Potential Commercial Applications: 

• Immunotherapeutics to treat 

cancers that overexpress CD70, such as 

renal cell carcinoma, glioblastoma, nonHodgkin’s lymphoma, and chronic 

lymphocytic leukemia. 

• A personalized cancer treatment 

strategy for patients whose tumor cells 

express CD70 whereby the patient’s own 

T cells are isolated, engineered to 

express the anti-CD70 CARs, and reinfused into the same patient to attack 

the tumor(s). 

Competitive Advantages: 

• CD70-specific CARs expressed on T 

cells will increase the likelihood of 

successful targeted therapy. 

• CAR–T cells target only CD70 

expressing cells and thus may generate 

fewer side effects than other cancer 

treatment approaches. 

• With the advent of Provenge(R), and 

Yervoy(R), immunotherapy is now more 

widely accepted as a viable cancer 

treatment option. 

• T-cell transfer can provide much 

larger numbers of anti-tumor immune 

cells compared to other approaches 

such as vaccines. 

Development Stage: 

• Early-stage. 

• In vitro data available. 

• In vivo data available (animal). 

Inventors: Qiong J. Wang, Zhiya Yu, 

James C. Yang (all of NCI). 

Publication: Wang QJ, et al. 

Distinctive features of the differentiated 

phenotype and infiltration of tumorreactive lymphocytes in clear cell renal 

cell carcinoma. Cancer Res. 2012 Dec 1; 

72(23):6119–29. [PMID 23071066] 

Intellectual Property: HHS Reference 

No. E–021–2015/0—U.S. Patent 

Application No. 62/088,882 filed 08 Dec 

2014. 

Licensing Contact: Whitney A. 

Hastings, Ph.D.; 301–451–7337; 

hastingw@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

mstockstill on DSK4VPTVN1PROD with NOTICES